Solanezumab

Last updated
Solanezumab
Monoclonal antibody
Type Whole antibody
Source Humanized
Target Beta amyloid
Clinical data
ATC code
  • none
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
Formula C6396H9922N1712O1996S42
Molar mass 144084.24 g·mol−1
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Solanezumab (proposed INN, LY2062430 [1] ) is a monoclonal antibody being investigated by Eli Lilly as a neuroprotector [2] for patients with Alzheimer's disease. [3] [4] The drug originally attracted extensive media coverage proclaiming it a breakthrough, but it has failed to show promise in Phase III trials. [5] [6]

Contents

Medical uses

Solanezumab was safely used in combination with approved Alzheimer's disease treatment, such as acetylcholinesterase inhibitors or memantine, in the clinical trials. [1] [7] [8]

Aside from Alzheimer's disease, there are other amyloid beta related diseases, in which solanezumab could be used, e.g., Down syndrome or cerebral amyloid angiopathy. [9] However, this has not been studied so far.

Adverse effects

No safety concerns were detected in any of the studies. [1] [7] [8] [10] A few patients suffered from mild infusion reactions that resolved on their own. [1] [7] The measured laboratory values and vital signs, showed no changes. [7] Other adverse events that occurred, e.g., headache or hematoma, were not considered as related to treatment. [1] [7]

Other anti-amyloid beta antibodies caused amyloid-related imaging abnormalities, [1] which is not the case for solanezumab. [1] [7] [8]

Pharmacology

Mechanism of action

Solanezumab binds the amyloid-β peptides that aggregate and form plaques in the brain that are an early pathological feature of Alzheimer's disease. [11] Solanezumab binds the central epitope of monomeric amyloid-β, KLVFFAED, (PDB ID 4XXD [12] ) with picomolar affinity. [13] This epitope is known as the nucleation site for Aβ oligomerization, and it is these oligomers of Aβ that are thought to be toxic to neurons.

Solanezumab is thought to act as an “amyloid beta sink” [14] that is “facilitating flux of amyloid beta from a central to peripheral compartment”. [14] This increases the peripheral elimination of both amyloid beta and the antibody. Amyloid beta plaques mostly consist of amyloid beta42. Solanezumab binds free amyloid beta which causes amyloid beta42 to solubilize to reestablish the equilibrium in the cerebrospinal fluid. [1]

Manufacturing

Solanezumab is expressed in Chinese hamster ovary cells. The produced antibodies are extracted and purified according to the standard procedures of the art. [9]

Society and culture

Commercial aspects

Solanezumab is developed and investigated by Eli Lilly and Company, Indianapolis, IN. [15] It is covered under the patent US 7,195,761 B2, which was filed in 2002 by Eli Lilly, Indianapolis, IN, and Washington University in St. Louis. [9]

In 2011, TPG-Axon Capital funded part of the phase 3 trials. It will receive an estimated $70 million of based on sales milestones after the launch of the product. [16]

Preclinical trials

The first evidence that antibodies binding the central amyloid beta domain are effective in the treatment of Alzheimer's disease was found in transgenic mice, which express the human amyloid beta precursor protein. Treatment with a murine analog of solanezumab (m266) lead to an increase in plasma amyloid beta, which was all bound to m266. Additionally, the amount of both free amyloid beta in the brain and amyloid beta in plaques was significantly decreased. [14]

Due to those results, it is postulated that m266 binds free amyloid beta in the plasma and, therefore, changes the amyloid beta equilibrium between plasma and brain. [14]

Clinical trials

Phase 1

In a single-dose, placebo-controlled study (H8A-LC-LZAH) in 19 patients with mild-to-moderate Alzheimer's disease, solanezumab was well tolerated over the whole dose range. There were no severe adverse drug reactions. All patients showed dose-dependent amyloid beta responses, but no change in cognition. This negative outcome was expected after only a single dose. [7]

Phase 2

52 patients with mild-to-moderate Alzheimer's disease underwent a parallel group, double-blind, randomized, placebo controlled phase 2 trial. They received weekly infusions of either saline or antibody for 12 weeks. The placebo group received only saline, whereas the antibody groups received four different concentrations of solanezumab infusions or saline. They were dosed with either 100 mg every 4 weeks, 100 mg weekly, 400 mg every 4 weeks or 400 mg weekly. [1]

Plasma amyloid beta levels increased dose dependently over the course of treatment. In the cerebrospinal fluid amyloid beta40 increased, whereas amyloid beta42 increased. This could be due to a change in equilibrium between plasma, cerebrospinal fluid and amyloid beta plaques. However, there were no significant changes in cognition and memory. [1]

Phase 3

Solanezumab was tested in two phase 3 clinical trials, EXPEDITION 1 and 2 (NCT00905372 and NCT00904683). Both were randomized, double-blind and placebo-controlled. Patients with mild-to-moderate Alzheimer's disease received either placebo or 400 mg solanezumab infusions every 4 weeks over 18 months. [8]

A total of 1012 patients participated in EXPEDITION 1, EXPEDITION 2 enrolled another 1040 patients. Both studies were not able to show a difference in cognition and memory between the treated and the placebo group. [8] However, a subgroup analysis of only patients with mild Alzheimer's disease showed less worsening of cognition in patients receiving solanezumab compared to placebo, which means the progression of the disease was slowed down. There was no effect on disease progression in patients with moderate symptoms. [10]

Since the first two EXPEDITION trials show a positive effect in patients with mild Alzheimer's disease, Lilly launched another phase 3 trial, EXPEDITION 3 (NCT01900665). Patients with mild Alzheimer's disease received 400 mg solanezumab every 4 weeks for 80 weeks. Afterwards they can continue treatment for a total of 208 weeks, if wanted. [17] This trial failed to show positive results, [18] despite the high expectations. The trial will be finalized in 2020. [17]

The Anti-Amyloid Treatment in Asymptomatic Alzheimer’s (A4) study is a phase 3 clinical trial to evaluate whether solanezumab can slow cognitive decline in cognitively unimpaired older adults with elevated levels of amyloid β. [19] [20] In July 2023, the final data showed that it did not slow cognitive decline as compared with placebo over a period of 240 weeks in persons with preclinical Alzheimer's disease. [21]

Related Research Articles

<span class="mw-page-title-main">Donepezil</span> Medication used for dementia

Donepezil, sold under the brand name Aricept among others, is a medication used to treat dementia of the Alzheimer's type. It appears to result in a small benefit in mental function and ability to function. Use, however, has not been shown to change the progression of the disease. Treatment should be stopped if no benefit is seen. It is taken by mouth or via a transdermal patch.

<span class="mw-page-title-main">Beta-secretase 1</span> Enzyme

Beta-secretase 1, also known as beta-site amyloid precursor protein cleaving enzyme 1, beta-site APP cleaving enzyme 1 (BACE1), membrane-associated aspartic protease 2, memapsin-2, aspartyl protease 2, and ASP2, is an enzyme that in humans is encoded by the BACE1 gene. Expression of BACE1 is observed mainly in neurons.

<span class="mw-page-title-main">Tarenflurbil</span> Chemical compound

Tarenflurbil, Flurizan or R-flurbiprofen, is a single enantiomer of the racemate NSAID flurbiprofen. For several years, research and trials for the drug were conducted by Myriad Genetics, to investigate its potential as a treatment for Alzheimer's disease; that investigation concluded in June 2008 when the company announced it would discontinue development of the compound.

<span class="mw-page-title-main">Monoclonal antibody therapy</span> Form of immunotherapy

Monoclonal antibodies (mAbs) have varied therapeutic uses. It is possible to create a mAb that binds specifically to almost any extracellular target, such as cell surface proteins and cytokines. They can be used to render their target ineffective, to induce a specific cell signal, to cause the immune system to attack specific cells, or to bring a drug to a specific cell type.

Bapineuzumab is a humanized monoclonal antibody that acts on the nervous system and may have potential therapeutic value for the treatment of Alzheimer's disease and possibly glaucoma. However, in 2012 it failed to produce significant cognitive improvements in patients in two major trials, despite lowering key biomarkers of AD, amyloid brain plaque and hyperphosphorylated tau protein in CSF.

<span class="mw-page-title-main">Latrepirdine</span> Antihistamine drug

Latrepirdine is an antihistamine drug which has been used clinically in Russia since 1983.

<span class="mw-page-title-main">Semagacestat</span> Chemical compound

Semagacestat (LY-450139) was a candidate drug for a causal therapy against Alzheimer's disease. It was originally developed by Eli Lilly and Elan, and clinical trials were conducted by Eli Lilly. Phase III trials included over 3000 patients, but in August 2010, a disappointing interim analysis, in which semagacestat performed worse than the placebo, led to the trials being stopped.

Alzheimer's Disease Neuroimaging Initiative (ADNI) is a multisite study that aims to improve clinical trials for the prevention and treatment of Alzheimer's disease (AD). This cooperative study combines expertise and funding from the private and public sector to study subjects with AD, as well as those who may develop AD and controls with no signs of cognitive impairment. Researchers at 63 sites in the US and Canada track the progression of AD in the human brain with neuroimaging, biochemical, and genetic biological markers. This knowledge helps to find better clinical trials for the prevention and treatment of AD. ADNI has made a global impact, firstly by developing a set of standardized protocols to allow the comparison of results from multiple centers, and secondly by its data-sharing policy which makes available all at the data without embargo to qualified researchers worldwide. To date, over 1000 scientific publications have used ADNI data. A number of other initiatives related to AD and other diseases have been designed and implemented using ADNI as a model. ADNI has been running since 2004 and is currently funded until 2021.

<span class="mw-page-title-main">PBT2</span> Chemical compound

PBT2 is a safe-for-human-use Zinc ionophore and an experimental drug candidate. It is a second-generation 8-hydroxyquinoline analog intended to be a successor to clioquinol and a potential treatment of Alzheimer's disease and Huntington's disease.

The Alzheimer's disease biomarkers are neurochemical indicators used to assess the risk or presence of the disease. The biomarkers can be used to diagnose Alzheimer's disease (AD) in a very early stage, but they also provide objective and reliable measures of disease progress. It is imperative to diagnose AD disease as soon as possible, because neuropathologic changes of AD precede the symptoms by years. It is well known that amyloid beta (Aβ) is a good indicator of AD disease, which has facilitated doctors to accurately pre-diagnose cases of AD. When Aβ peptide is released by proteolytic cleavage of amyloid-beta precursor protein, some Aβ peptides that are solubilized are detected in CSF and blood plasma which makes AB peptides a promising candidate for biological markers. It has been shown that the amyloid beta biomarker shows 80% or above sensitivity and specificity, in distinguishing AD from dementia. It is believed that amyloid beta as a biomarker will provide a future for diagnosis of AD and eventually treatment of AD.

<span class="mw-page-title-main">Rivastigmine</span> Chemical compound

Rivastigmine is a cholinesterase inhibitor used for the treatment of mild to moderate Alzheimer's disease. The drug can be administered orally or via a transdermal patch; the latter form reduces the prevalence of side effects, which typically include nausea and vomiting.

Crenezumab is a fully humanized monoclonal antibody against human 1-40 and 1-42 beta amyloid, which is being investigated as a treatment of Alzheimer's disease. Crenezumab is highly homologous to solanezumab, another monoclonal antibody targeting amyloid-β peptides. In June 2022, the US National Institutes of Health announced that the drug failed as a medication for early-onset Alzheimer's disease following the results of a decade-long clinical trial.

Florbetaben, a fluorine-18 (18F)-labeled stilbene derivative, trade name NeuraCeq, is a diagnostic radiotracer developed for routine clinical application to visualize β-amyloid plaques in the brain. It is indicated for Positron Emission Tomography (PET) imaging of β-amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD) and other causes of cognitive impairment. β-amyloid is a key neuropathological hallmark of AD, so markers of β-amyloid plaque accumulation in the brain are useful in distinguishing AD from other causes of dementia. The tracer successfully completed a global multicenter phase 0–III development program and obtained approval in Europe, US and South Korea in 2014.

Lecanemab, sold under the brand name Leqembi, is a monoclonal antibody medication used for the treatment of Alzheimer's disease. Lecanemab is an amyloid beta-directed antibody. It is given via intravenous infusion. The most common side effects of lecanemab include headache, infusion-related reactions, and amyloid-related imaging abnormalities, a side effect known to occur with the class of antibodies targeting amyloid.

<span class="mw-page-title-main">Phenserine</span> Chemical compound

Phenserine is a synthetic drug which has been investigated as a medication to treat Alzheimer's disease (AD), as the drug exhibits neuroprotective and neurotrophic effects.

<span class="mw-page-title-main">David M. Holtzman</span> Medical researcher

David M. Holtzman is an American physician-scientist known for his work exploring the biological mechanisms underlying neurodegeneration, with a focus on Alzheimer's disease. Holtzman is former Chair of the Department of Neurology, Scientific Director of the Hope Center for Neurological Disorders, and associate director of the Knight Alzheimer's Disease Research Center at Washington University School of Medicine in St. Louis, Missouri. Holtzman's lab is known for examining how apoE4 contributes to Alzheimer's disease as well as how sleep modulates amyloid beta in the brain. His work has also examined the contributions of microglia to AD pathology.

Donanemab is a biological drug in Phase III clinical trials to determine whether it slows the progression of early Alzheimer's disease. Donanemab has shown positive results in its first trials. Donanemab was developed by the Eli Lilly and Co. and is under clinical development as a possible treatment for Alzheimer's disease. There is currently no approved cure or disease-modifying treatment for Alzheimer's disease except for lecanemab.

<span class="mw-page-title-main">Simufilam</span> Experimental drug for Alzheimers disease

Simufilam (PTI-125) is an Investigational New Drug for the treatment of Alzheimer's disease. It is being developed by the American pharmaceutical firm Cassava Sciences. The drug is in phase III clinical trials as of October 2023. There are two phase III clinical studies: RETHINK-ALZ, a 52-week trial, is set to complete in 2024, and REFOCUS-ALZ, spanning 76 weeks, is projected to finish in 2025.

<span class="mw-page-title-main">Buntanetap</span> Chemical compound

Buntanetap is an orally-administered small molecule inhibitor of several neurotoxic proteins that is under investigation in the treatment of Alzheimer's disease, frontotemporal dementia, chronic traumatic encephalopathy and Parkinson's disease. It is the (+) enantiomer of phenserine, as the (-) enantiomer also has unwanted anticholinergic effects. It is currently in phase III trials for the treatment of Parkinson's.

Anti-amyloid drugs, also known as anti-amyloid antibodies (AAA), are a class of monoclonal antibodies developed to treat Alzheimer's disease. The first drug in the class to be developed, in the early 2000s, was bapineuzumab, but it did not show effectiveness in later-stage trials. The first drug to be FDA approved was aducanumab in 2021.

References

  1. 1 2 3 4 5 6 7 8 9 10 Farlow M, Arnold SE, van Dyck CH, Aisen PS, Snider BJ, Porsteinsson AP, et al. (July 2012). "Safety and biomarker effects of solanezumab in patients with Alzheimer's disease". Alzheimer's & Dementia. 8 (4): 261–271. doi:10.1016/j.jalz.2011.09.224. PMID   22672770. S2CID   12755108.
  2. ↑ International Nonproprietary Names for Pharmaceutical Substances (INN, prepublication copy), World Health Organization.
  3. ↑ Clinical trial number NCT00749216 for "Solanezumab Safety Study in Japanese Patients With Alzheimer's Disease" at ClinicalTrials.gov
  4. ↑ Clinical trial number NCT00905372 for "Effect of LY2062430 on the Progression of Alzheimer's Disease (EXPEDITION)" at ClinicalTrials.gov
  5. ↑ McCartney M (July 2015). "Margaret McCartney: The "breakthrough" drug that's not been shown to help in Alzheimer's disease". BMJ. 351: h4064. doi: 10.1136/bmj.h4064 . PMID   26208710.
  6. ↑ Meglio M (March 10, 2023). "Solanezumab Fails Phase 3 A4 Study of Preclinical Alzheimer Disease". NeurologyLive. Retrieved August 1, 2023.
  7. 1 2 3 4 5 6 7 Siemers ER, Friedrich S, Dean RA, Gonzales CR, Farlow MR, Paul SM, Demattos RB (2010). "Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease". Clinical Neuropharmacology. 33 (2): 67–73. doi:10.1097/WNF.0b013e3181cb577a. PMID   20375655. S2CID   43700412.
  8. 1 2 3 4 5 Bates ML, Farrell ET, Eldridge MW (February 2014). "Abnormal ventilatory responses in adults born prematurely". The New England Journal of Medicine. 370 (6): 584–585. doi:10.1056/nejmx140041. PMC   4769592 . PMID   24499235.
  9. 1 2 3 US 7195761,"Humanized antibodies that sequester abeta peptide",issued 27 March 2007, assigned to Eli Lilly and Co.and Washington University in St Louis
  10. 1 2 Siemers ER, Sundell KL, Carlson C, Case M, Sethuraman G, Liu-Seifert H, et al. (February 2016). "Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients". Alzheimer's & Dementia. 12 (2): 110–120. doi: 10.1016/j.jalz.2015.06.1893 . PMID   26238576. S2CID   19557687.
  11. ↑ Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. (Australian Imaging Biomarkers Lifestyle (AIBL) Research Group) (April 2013). "Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study". The Lancet. Neurology. 12 (4): 357–367. doi:10.1016/S1474-4422(13)70044-9. PMID   23477989. S2CID   18181917.
  12. ↑ Crespi GA, Hermans SJ, Parker MW, Miles LA (April 2015). "Molecular basis for mid-region amyloid-β capture by leading Alzheimer's disease immunotherapies". Scientific Reports. 5: 9649. Bibcode:2015NatSR...5E9649C. doi:10.1038/srep09649. PMC   4549621 . PMID   25880481.
  13. ↑ Watt AD, Crespi GA, Down RA, Ascher DB, Gunn A, Perez KA, et al. (2014). "Do current therapeutic anti-Aβ antibodies for Alzheimer's disease engage the target?". Acta Neuropathologica. 127 (6): 803–810. doi:10.1007/s00401-014-1290-2. hdl: 11343/198431 . PMID   24803227. S2CID   20139520.
  14. 1 2 3 4 DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM (July 2001). "Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease". Proceedings of the National Academy of Sciences of the United States of America. 98 (15): 8850–8855. Bibcode:2001PNAS...98.8850D. doi: 10.1073/pnas.151261398 . PMC   37524 . PMID   11438712.
  15. ↑ "Lilly Integrated report 2015" (PDF). lilly.com. Eli Lilly. 2016-11-10. Retrieved 2016-11-10.
  16. ↑ "Eli Lilly Annual Report 2015" (PDF). Eli Lilly. 2016-11-10. Retrieved 2016-11-10.
  17. 1 2 Clinical trial number NCT01900665 for "Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo" at ClinicalTrials.gov
  18. ↑ "Lilly Announces Top-Line Results of Solanezumab Phase 3 Clinical Trial". Eli Lilly. Retrieved 23 November 2016.
  19. ↑ Sperling RA, Donohue MC, Raman R, Sun CK, Yaari R, Holdridge K, et al. (June 2020). "Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals". JAMA Neurology. 77 (6): 735–745. doi:10.1001/jamaneurol.2020.0387. PMC   7136861 . PMID   32250387.
  20. ↑ Insel PS, Donohue MC, Sperling R, Hansson O, Mattsson-Carlgren N (May 2020). "The A4 study: β-amyloid and cognition in 4432 cognitively unimpaired adults". Annals of Clinical and Translational Neurology. 7 (5): 776–785. doi: 10.1002/acn3.51048 . PMC   7261742 . PMID   32315118.
  21. ↑ Sperling RA, Donohue MC, Raman R, Rafii MS, Johnson K, Masters CL, et al. (September 2023). "Trial of Solanezumab in Preclinical Alzheimer's Disease". The New England Journal of Medicine. 389 (12): 1096–1107. doi:10.1056/NEJMoa2305032. PMC  10559996. PMID   37458272.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.